Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity

Next Previous
Trial Profile

Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolcapone (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors SOM Biotech

Most Recent Events

  • 29 Nov 2016 Status changed from recruiting to completed.
  • 21 Apr 2016 Results of Phase IIa part (n=21) presented at the 68th Annual Meeting of the American Academy of Neurology.
  • 26 May 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Jul 2015, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top